Adagene Inc. Files 6-K with Mid-Year Financial Updates

Ticker: ADAG · Form: 6-K · Filed: Jul 25, 2024 · CIK: 1818838

Sentiment: neutral

Topics: financial-update, 6-k, sec-filing

TL;DR

Adagene's 6-K shows Q2 financial snapshot; check capital structure changes.

AI Summary

Adagene Inc. filed a 6-K report for the period ending June 30, 2024. The filing includes financial data for the first six months of 2024 and the comparable period in 2023, detailing changes in common stock, additional paid-in capital, treasury stock, retained earnings, and accumulated other comprehensive income. Specific dollar amounts for these accounts are presented as of June 30, 2024, and December 31, 2023.

Why It Matters

This filing provides investors with an update on Adagene's financial position as of the end of the second quarter, offering insights into the company's capital structure and retained earnings.

Risk Assessment

Risk Level: low — This is a routine financial filing (6-K) providing an update on the company's financial position, not announcing major strategic shifts or significant events.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 6-K filing?

The primary purpose of this 6-K filing is to provide an update on Adagene Inc.'s financial position as of June 30, 2024, including details on its capital structure and equity accounts for the period ending June 30, 2024, and comparative periods.

What financial periods are covered in this filing?

This filing covers the period from January 1, 2024, to June 30, 2024, and includes comparative data for the period from January 1, 2023, to June 30, 2023, as well as year-end data for December 31, 2023.

What specific financial accounts are detailed in the filing?

The filing details accounts such as Common Stock, Additional Paid-In Capital, Treasury Stock (Common), Retained Earnings, and Accumulated Other Comprehensive Income.

What is Adagene Inc.'s SIC code?

Adagene Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

When was this 6-K form filed with the SEC?

This 6-K form was filed with the SEC on July 25, 2024.

Filing Stats: 351 words · 1 min read · ~1 pages · Grade level 11 · Accepted 2024-07-25 16:05:54

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. VNET Group, Inc. By: /s/ Peter Luo Name: Peter Luo Title: Chief Executive Officer Date: July 25, 2024 EXHIBIT INDEX Exhibit Description 99.1 Press release tilted "Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update" 99.2 Unaudited Interim Condensed Consolidated Financial Statements for the six months ended June 30, 2023 and 2024 101.INS Inline XBRL Instance Document – this instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document 101.SCH Inline XBRL Taxonomy Extension Schema 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase 101.LAB Inline XBRL Taxonomy Extension Label Linkbase 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase 104 Cover Page Interactive Data File (embedded within the Inline IXBRL document)

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing